0001562180-23-001537.txt : 20230217
0001562180-23-001537.hdr.sgml : 20230217
20230217204433
ACCESSION NUMBER: 0001562180-23-001537
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20230215
FILED AS OF DATE: 20230217
DATE AS OF CHANGE: 20230217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Agarwal Vikas
CENTRAL INDEX KEY: 0001937373
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39203
FILM NUMBER: 23644970
MAIL ADDRESS:
STREET 1: C/O 1LIFE HEALTHCARE, INC.
STREET 2: ONE EMBARCADERO CENTER SUITE 1900
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94111
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: 1Life Healthcare Inc
CENTRAL INDEX KEY: 0001404123
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
IRS NUMBER: 760707204
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE EMBARCADERO CENTER, SUITE 1900
CITY: San Francisco
STATE: CA
ZIP: 94111
BUSINESS PHONE: (415) 814-0927
MAIL ADDRESS:
STREET 1: ONE EMBARCADERO CENTER, SUITE 1900
CITY: San Francisco
STATE: CA
ZIP: 94111
FORMER COMPANY:
FORMER CONFORMED NAME: 1life Healthcare Inc
DATE OF NAME CHANGE: 20070621
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2023-02-15
false
0001404123
1Life Healthcare Inc
ONEM
0001937373
Agarwal Vikas
C/O 1LIFE HEALTHCARE, INC.
ONE EMBARCADERO CENTER, SUITE 1900
SAN FRANCISCO
CA
94111
false
true
false
false
Chief Accounting Officer
Common Stock
2023-02-15
4
M
false
4303.00
A
10154.00
D
Common Stock
2023-02-15
4
M
false
829.00
A
10983.00
D
Common Stock
2023-02-16
4
S
false
2117.00
15.356
D
8866.00
D
Restricted Stock Units
2023-02-15
4
M
false
4303.00
0.00
D
Common Stock
4303.00
12907.00
D
Restricted Stock Units
2023-02-15
4
M
false
829.00
0.00
D
Common Stock
829.00
1658.00
D
Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Restricted stock units ("RSUs") convert into the issuer's common stock on a one-for-one basis.
Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the reporting person.
This transaction was executed in multiple trades at prices ranging from $15.31 to $15.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The RSUs vest in equal annual installments over four years on the anniversary of the vesting commencement date, subject to the reporting person's continuous service as of each such date.
/s/ Ivy Tseng, Attorney-in-Fact for Vikas Agarwal
2023-02-17
EX-24
2
vagarwalpoa.txt
POA
POWER OF ATTORNEY
(For Executing Form ID and Forms 3, 4 and 5)
Know all by these presents, that the undersigned hereby
constitutes and appoints each of BJORN B. THALER, MATTHEW B.
HEMINGTON, LISA A. MANGO, IVY TSENG, MILSON YU and KRIS TAMASHIRO,
signing individually, the undersigned's true and lawful attorneys-in
fact and agents to:
(1) execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer, director or beneficial owner of
more than 10% of a registered class of securities of 1Life
Healthcare, Inc. (the "Company"), Forms 3, 4 and 5 (including any
amendments thereto) in accordance with Section 16(a) of the
Securities Exchange Act of 1934, as amended (the "Exchange Act") and
the rules thereunder and a Form ID, Uniform Application for Access
Codes to File on EDGAR;
(2) do and perform any and all acts for and on behalf of the
undersigned that may be necessary or desirable to execute such Forms
3, 4 or 5 or Form ID
(including any amendments thereto) and timely file such forms with
the United
States Securities and Exchange Commission and any stock exchange or
similar
authority; and
(3) take any other action of any nature whatsoever in connection
with the
foregoing which, in the opinion of such attorney-in-fact, may be of
benefit, in the best interest of, or legally required by, the
undersigned, it being
understood that the documents executed by such attorney-in-fact on
behalf of the undersigned pursuant to this Power of Attorney shall be
in such form and shall contain such terms and conditions as such
attorney-in-fact may approve in such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact
full power and authority to do and perform any and every act and
thing whatsoever requisite, necessary or proper to be done in the
exercise of any of the rights and powers herein granted, as fully to
all intents and purposes as the undersigned might or could do if
personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or
such attorney-in-fact's substitute or substitutes, shall lawfully do
or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned acknowledges that
the foregoing attorneys-in-fact, in serving in such capacity at the
request of the undersigned, are not assuming, nor is the Company
assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect
until the earliest to occur of (a) the undersigned is no longer
required to file Forms 3, 4 and 5 with respect to the undersigned's
holdings of and transactions in securities issued by the Company, (b)
revocation by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact or (c) as to any attorney-in-fact
individually, until such attorney-in-fact is no longer employed by
the Company or Cooley LLP.
IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of July 5, 2022.
/s/ Vikas Agarwal
Vikas Agarwal